Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Size Matters and How You Measure It: A Gram-Negative Antibacterial Example Exceeding Typical Molecular Weight Limits.

Ruggiu F, Yang S, Simmons RL, Casarez A, Jones AK, Li C, Jansen JM, Moser HE, Dean CR, Reck F, Lindvall M.

ACS Infect Dis. 2019 Oct 11;5(10):1688-1692. doi: 10.1021/acsinfecdis.9b00256. Epub 2019 Sep 3.

PMID:
31478369
2.
3.

[Effects of Changes in Healthcare on Doctors and Patients using the Example of Ukraine].

Bogodistov Y, Reck FM, Moormann J, Krupskyi OP.

Gesundheitswesen. 2019 Jun 11. doi: 10.1055/a-0894-4775. [Epub ahead of print] German.

PMID:
31185497
4.

A Unified Framework for the Incorporation of Bioorthogonal Compound Exposure Probes within Biological Compartments.

Spangler B, Yang S, Baxter Rath CM, Reck F, Feng BY.

ACS Chem Biol. 2019 Apr 19;14(4):725-734. doi: 10.1021/acschembio.9b00008. Epub 2019 Apr 5.

PMID:
30908011
5.

IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor.

Reck F, Bermingham A, Blais J, Casarez A, Colvin R, Dean CR, Furegati M, Gamboa L, Growcott E, Li C, Lopez S, Metzger L, Nocito S, Ossola F, Phizackerley K, Rasper D, Shaul J, Shen X, Simmons RL, Tang D, Tashiro K, Yue Q.

ACS Infect Dis. 2019 Jul 12;5(7):1045-1051. doi: 10.1021/acsinfecdis.9b00031. Epub 2019 Mar 27.

PMID:
30861342
6.

Impact of Inducible blaDHA-1 on Susceptibility of Klebsiella pneumoniae Clinical Isolates to LYS228 and Identification of Chromosomal mpl and ampD Mutations Mediating Upregulation of Plasmid-Borne blaDHA-1 Expression.

Jones AK, Ranjitkar S, Lopez S, Li C, Blais J, Reck F, Dean CR.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01202-18. doi: 10.1128/AAC.01202-18. Print 2018 Oct.

7.

Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae.

Dean CR, Barkan DT, Bermingham A, Blais J, Casey F, Casarez A, Colvin R, Fuller J, Jones AK, Li C, Lopez S, Metzger LE 4th, Mostafavi M, Prathapam R, Rasper D, Reck F, Ruzin A, Shaul J, Shen X, Simmons RL, Skewes-Cox P, Takeoka KT, Tamrakar P, Uehara T, Wei JR.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01200-18. doi: 10.1128/AAC.01200-18. Print 2018 Oct.

8.

In Vitro Activity of LYS228, a Novel Monobactam Antibiotic, against Multidrug-Resistant Enterobacteriaceae.

Blais J, Lopez S, Li C, Ruzin A, Ranjitkar S, Dean CR, Leeds JA, Casarez A, Simmons RL, Reck F.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00552-18. doi: 10.1128/AAC.00552-18. Print 2018 Oct.

9.

Molecular Probes for the Determination of Subcellular Compound Exposure Profiles in Gram-Negative Bacteria.

Spangler B, Dovala D, Sawyer WS, Thompson KV, Six DA, Reck F, Feng BY.

ACS Infect Dis. 2018 Sep 14;4(9):1355-1367. doi: 10.1021/acsinfecdis.8b00093. Epub 2018 Jun 15.

PMID:
29846057
10.

Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae - Identification of LYS228.

Reck F, Bermingham A, Blais J, Capka V, Cariaga T, Casarez A, Colvin R, Dean CR, Fekete A, Gong W, Growcott E, Guo H, Jones AK, Li C, Li F, Lin X, Lindvall M, Lopez S, McKenney D, Metzger L, Moser HE, Prathapam R, Rasper D, Rudewicz P, Sethuraman V, Shen X, Shaul J, Simmons RL, Tashiro K, Tang D, Tjandra M, Turner N, Uehara T, Vitt C, Whitebread S, Yifru A, Zang X, Zhu Q.

Bioorg Med Chem Lett. 2018 Feb 15;28(4):748-755. doi: 10.1016/j.bmcl.2018.01.006. Epub 2018 Jan 4.

PMID:
29336873
11.

Synthesis of ciprofloxacin dimers for evaluation of bacterial permeability in atypical chemical space.

Ross AG, Benton BM, Chin D, De Pascale G, Fuller J, Leeds JA, Reck F, Richie DL, Vo J, LaMarche MJ.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3468-75. doi: 10.1016/j.bmcl.2015.07.010. Epub 2015 Jul 9.

PMID:
26189081
12.

Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.

Ravishankar S, Ambady A, Awasthy D, Mudugal NV, Menasinakai S, Jatheendranath S, Guptha S, Sharma S, Balakrishnan G, Nandishaiah R, Ramachandran V, Eyermann CJ, Reck F, Rudrapatna S, Sambandamurthy VK, Sharma UK.

Tuberculosis (Edinb). 2015 Sep;95(5):589-98. doi: 10.1016/j.tube.2015.05.004. Epub 2015 May 27.

PMID:
26073894
13.

Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.

Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE.

Antimicrob Agents Chemother. 2015 Jan;59(1):331-7. doi: 10.1128/AAC.04077-14. Epub 2014 Oct 27.

14.

Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.

Gao N, McLeod SM, Hajec L, Olivier NB, Lahiri SD, Bryan Prince D, Thresher J, Ross PL, Whiteaker JD, Doig P, Li AH, Hill PJ, Cornebise M, Reck F, Hale MR.

Protein Expr Purif. 2014 Dec;104:57-64. doi: 10.1016/j.pep.2014.09.006. Epub 2014 Sep 18.

PMID:
25240855
15.

Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

Reck F, Ehmann DE, Dougherty TJ, Newman JV, Hopkins S, Stone G, Agrawal N, Ciaccio P, McNulty J, Barthlow H, O'Donnell J, Goteti K, Breen J, Comita-Prevoir J, Cornebise M, Cronin M, Eyermann CJ, Geng B, Carr GR, Pandarinathan L, Tang X, Cottone A, Zhao L, Bezdenejnih-Snyder N.

Bioorg Med Chem. 2014 Oct 1;22(19):5392-409. doi: 10.1016/j.bmc.2014.07.040. Epub 2014 Aug 4.

PMID:
25155913
16.

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE.

Antimicrob Agents Chemother. 2014 May;58(5):2657-64. doi: 10.1128/AAC.02778-13. Epub 2014 Feb 24. Erratum in: Antimicrob Agents Chemother. 2014 Jul;58(7):4250.

17.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.

Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL.

J Med Chem. 2012 Aug 9;55(15):6916-33. doi: 10.1021/jm300690s. Epub 2012 Jul 20.

PMID:
22779424
18.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.

Reck F, Alm R, Brassil P, Newman J, Dejonge B, Eyermann CJ, Breault G, Breen J, Comita-Prevoir J, Cronin M, Davis H, Ehmann D, Galullo V, Geng B, Grebe T, Morningstar M, Walker P, Hayter B, Fisher S.

J Med Chem. 2011 Nov 24;54(22):7834-47. doi: 10.1021/jm2008826. Epub 2011 Oct 27.

PMID:
21999508
19.

Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors.

Geng B, Comita-Prevoir J, Eyermann CJ, Reck F, Fisher S.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5432-5. doi: 10.1016/j.bmcl.2011.06.126. Epub 2011 Jul 2.

PMID:
21782427
20.
21.

[Analysis of 10-year survival after flexion osteotomy for femoral head necrosis].

Reck F, Thorey F, Lewinski GV, Windhagen H.

Z Orthop Unfall. 2007 Jul-Aug;145(4):448-51. German.

PMID:
17912664
22.

Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.

Reck F, Zhou F, Eyermann CJ, Kern G, Carcanague D, Ioannidis G, Illingworth R, Poon G, Gravestock MB.

J Med Chem. 2007 Oct 4;50(20):4868-81. Epub 2007 Aug 28.

PMID:
17722903
23.

Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A.

Reck F, Zhou F, Girardot M, Kern G, Eyermann CJ, Hales NJ, Ramsay RR, Gravestock MB.

J Med Chem. 2005 Jan 27;48(2):499-506.

PMID:
15658863
24.
25.

Liposomal delivery of antigen to human dendritic cells.

Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM.

Vaccine. 2003 Feb 14;21(9-10):883-90.

PMID:
12547598
26.

Biochemical characterization of a phosphinate inhibitor of Escherichia coli MurC.

Marmor S, Petersen CP, Reck F, Yang W, Gao N, Fisher SL.

Biochemistry. 2001 Oct 9;40(40):12207-14.

PMID:
11580296
27.

Pentopyranosyl oligonucleotide systems. Part 11: Systems with shortened backbones: (D)-beta-ribopyranosyl-(4'-->3')- and (L)-alpha-lyxopyranosyl-(4'-->3')-oligonucleotides.

Wippo H, Reck F, Kudick R, Ramaseshan M, Ceulemans G, Bolli M, Krishnamurthy R, Eschenmoser A.

Bioorg Med Chem. 2001 Sep;9(9):2411-28.

PMID:
11553483
28.

Inhibitors of the bacterial cell wall biosynthesis enzyme MurC.

Reck F, Marmor S, Fisher S, Wuonola MA.

Bioorg Med Chem Lett. 2001 Jun 4;11(11):1451-4.

PMID:
11378375
29.

L-alpha-lyxopyranosyl (4'-->3') oligonucleotides: a base-pairing system containing a shortened backbone.

Reck F, Wippo H, Kudick R, Bolli M, Ceulemans G, Krishnamurthy R, Eschenmoser A.

Org Lett. 1999 Nov 18;1(10):1531-4.

PMID:
10836020
31.

Chemical etiology of nucleic acid structure: comparing pentopyranosyl-(2'-->4') oligonucleotides with RNA.

Beier M, Reck F, Wagner T, Krishnamurthy R, Eschenmoser A.

Science. 1999 Jan 29;283(5402):699-703.

32.

Expression of stable human O-glycan core 2 beta-1,6-N-acetylglucosaminyltransferase in Sf9 insect cells.

Toki D, Sarkar M, Yip B, Reck F, Joziasse D, Fukuda M, Schachter H, Brockhausen I.

Biochem J. 1997 Jul 1;325 ( Pt 1):63-9.

33.

Synthetic substrate analogues for UDP-GlcNAc: Man alpha 1-3R beta 1-2-N-acetylglucosaminyltransferase I. Substrate specificity and inhibitors for the enzyme.

Reck F, Springer M, Meinjohanns E, Paulsen H, Brockhausen I, Schachter H.

Glycoconj J. 1995 Dec;12(6):747-54.

PMID:
8748150
35.

[Synthesis of modified tetrasaccharides as analog acceptor-inhibitors of N-acetylglucosaminyltransferase II].

Paulsen H, Springer M, Reck F, Brockhausen I, Schachter H.

Carbohydr Res. 1995 Oct 2;275(2):403-11. German. No abstract available.

PMID:
8529232
38.

Substrate specificity and inhibition of UDP-GlcNAc:GlcNAc beta 1-2Man alpha 1-6R beta 1,6-N-acetylglucosaminyltransferase V using synthetic substrate analogues.

Brockhausen I, Reck F, Kuhns W, Khan S, Matta KL, Meinjohanns E, Paulsen H, Shah RN, Baker MA, Schachter H.

Glycoconj J. 1995 Jun;12(3):371-9.

PMID:
7496152
40.

Synthetic substrate analogues for UDP-GlcNAc: Man alpha 1-6R beta(1-2)-N-acetylglucosaminyltransferase II. Substrate specificity and inhibitors for the enzyme.

Reck F, Meinjohanns E, Springer M, Wilkens R, Van Dorst JA, Paulsen H, Möller G, Brockhausen I, Schachter H.

Glycoconj J. 1994 Jun;11(3):210-6. Erratum in: Glycoconj J 1994 Dec;11(6):i.

PMID:
7841796
41.

Inhibition of UDP-GlcNAc:Gal beta 1-3GalNAc-R (GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase from acute myeloid leukaemia cells by photoreactive nitrophenyl substrate derivatives.

Toki D, Granovsky MA, Reck F, Kuhns W, Baker MA, Matta KL, Brockhausen I.

Biochem Biophys Res Commun. 1994 Jan 28;198(2):417-23.

PMID:
7802860
42.

[Synthesis of modified oligosaccharides of the N-glycoprotein as substrate for N-acetylglucosaminyltransferase I].

Paulsen H, Reck F, Brockhausen I.

Carbohydr Res. 1992 Dec 15;236:39-71. German.

PMID:
1291062
43.

Control of glycoprotein synthesis: substrate specificity of rat liver UDP-GlcNAc:Man alpha 3R beta 2-N-acetylglucosaminyltransferase I using synthetic substrate analogues.

Möller G, Reck F, Paulsen H, Kaur KJ, Sarkar M, Schachter H, Brockhausen I.

Glycoconj J. 1992 Aug;9(4):180-90.

PMID:
1422138

Supplemental Content

Support Center